NVAX Stock Forecast: Global Rollout Of Covid-19 Vaccines & Buy Rating

Viktoria VoronchukThis NVAX stock prediction article was written by Viktoriya Voronchuk – Financial Analyst intern I Know First.


  • Over the past month, the NVAX stock is up 69%: Investors believe Novavax is a major competitor for the vaccine from covid-19
  • Novavax spent 113,84 thousand $ on research and development: more than competitors in the biotech sector
  • The average growth rate for the last 8 years shows that NVAX 's stock target price should be around 145.15 $ for the next year

premiumRead The FullPremium Article

Subscribe to receive exclusive PREMIUM content here